Roche, Polyphor sign $548M deal to develop superbug antibiotic

11/4/2013 | Reuters

Roche Holding has signed a $548 million agreement with Polyphor for the development and commercialization of experimental antibiotic POL7080 to fight drug-resistant infections in hospitals. Under the deal, Roche will pay $38.4 million upfront. In addition, Polyphor is entitled to receive double-digit royalties on product sales.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX